Related Experiment Video

Updated: May 12, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

[Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer]

A-C Toffart1, L Sakhri, D Moro-Sibilot

  • 1UM Oncologie Thoracique, pôle Cancérologie Médecine Aiguë et Communautaire, Centre Hospitalier Universitaire A.-Michallon, BP 217, 38043 Grenoble cedex 9, France. AToffart@chu-grenoble.fr

Revue De Pneumologie Clinique
|April 9, 2013
PubMed

Insights

Crizotinib effectively treats non-small cell lung cancer with EML4-ALK rearrangement, showing good disease control and tolerability in clinical trials. This targeted therapy offers a promising option for patients with this specific genetic mutation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) harbors specific genetic alterations, including the echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase (EML4-ALK) fusion gene.
  • The EML4-ALK rearrangement is a key driver mutation in a subset of NSCLC patients, making it a target for precision medicine.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK-rearranged NSCLC.
  • To provide an overview of the clinical trial data supporting the use of crizotinib for this specific patient population.

Main Methods:

  • Clinical trials (Phase I to III) were conducted to assess crizotinib's safety and effectiveness.
  • The EML4-ALK fusion gene was detected using a break-apart fluorescence in situ hybridization (FISH) assay.

Main Results:

  • Crizotinib demonstrated an interesting disease control rate in patients with ALK-positive NSCLC.
  • The drug exhibited acceptable tolerability profiles across the studied patient groups.
  • Crizotinib is currently available in France under temporary use authorization.

Conclusions:

  • Crizotinib is an effective targeted therapy for NSCLC patients with the EML4-ALK rearrangement.
  • Ongoing research is exploring new therapeutic agents for ALK-positive NSCLC, indicating a dynamic field of development.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...